ArticleFrontiers in oncology2022

The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer.

Ryan M Finnegan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.